Government ContextGovernment Context
ActivityRulesGrantsPress releasesHearingsBills
ViewsAgenciesTopicsOrganizationsCommitteesLegislators
PricingLog inCreate account
Details

Opioid Analgesic Drugs: Considerations for Benefit- Risk Assessment Framework; Guidance for Industry; Draft Guidance

FDA-2019-D-1536-0002Other
Document

Details

The document's own metadata, straight from the source system.

Title
Opioid Analgesic Drugs: Considerations for Benefit- Risk Assessment Framework; Guidance for Industry; Draft Guidance
Posted
Jun 20, 2019
Agency
Food and Drug Administration (FDA)
View on regulations.gov ↗